Lista de obras -

10th anniversary of the Austrian MDS Platform: aims and ongoing projects.

artículo científico publicado en 2014

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

artículo científico publicado en 2017

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

artículo científico publicado en 2016

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

artículo científico publicado en 2014

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

artículo científico publicado en 2014

Azacitidine in adult patients with acute myeloid leukemia

artículo científico

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group ⬇️

artículo científico publicado el 29 de abril de 2013

Basidiomycete metabolites attenuate virulence properties of Candida albicans in vitro.

artículo científico publicado en 2008

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

artículo científico publicado en 2017

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group

artículo científico publicado en 2018

Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia ⬇️

artículo científico publicado el 5 de enero de 2013

Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab

artículo científico publicado en 2011

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome

artículo científico publicado en 2013

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

artículo científico publicado en 2018

Digging deep into "dirty" drugs - modulation of the methylation machinery

artículo científico publicado en 2015

Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia

artículo científico publicado en 2018

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM

artículo científico publicado en 2019

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia

artículo científico publicado en 2018

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

article published in 2018

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

artículo científico publicado en 2018

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C

artículo científico publicado en 2007

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

artículo científico publicado en 2016

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

artículo científico publicado en 2009

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

article by Michael Leisch et al published 21 February 2019 in Cancers

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

artículo científico

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights

artículo científico publicado en 2009

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

scientific article published on 02 May 2019

Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation

artículo científico publicado en 2017

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

artículo científico publicado en 2017

Remission maintenance treatment options in chronic lymphocytic leukemia

scientific article published on 10 August 2018

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial

scientific article published on 19 March 2019

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

artículo científico publicado en 2016

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

artículo científico publicado en 2018

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - An analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie

scientific article published on 01 June 2017

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

artículo científico publicado en 2018

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial

artículo científico publicado en 2018

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia

artículo científico publicado en 2017

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation

scientific article published on 31 March 2017

The impact of storage effects in biobanks on biomarker discovery in systems biology studies

artículo científico publicado en 2010

Time to repeal and replace response criteria for acute myeloid leukemia?

artículo científico publicado en 2018

Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

artículo científico publicado en 2014

Tumour-immune cell interactions modulated by chemokines

artículo científico publicado en 2008

Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.

artículo científico publicado en 2009

Lista de obras de

10th anniversary of the Austrian MDS Platform: aims and ongoing projects.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

Azacitidine in adult patients with acute myeloid leukemia

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group ⬇️

Basidiomycete metabolites attenuate virulence properties of Candida albicans in vitro.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group

Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia ⬇️

Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Digging deep into "dirty" drugs - modulation of the methylation machinery

Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Remission maintenance treatment options in chronic lymphocytic leukemia

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - An analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation

The impact of storage effects in biobanks on biomarker discovery in systems biology studies

Time to repeal and replace response criteria for acute myeloid leukemia?

Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

Tumour-immune cell interactions modulated by chemokines

Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.